ArticleUse of aromatase inhibitors in poor-responder patients receiving GnRH antagonist protocols☆
Introduction
Poor ovarian response to standard ovulation induction protocols, which mainly reflects diminished ovarian reserve, still remains as a major challenge in assisted reproduction. The clinical outcomes of assisted reproduction were reported as negatively affected in cases with poor ovarian response; however, the definition of poor response is still controversial (Kailasam, Muasher). Increased cycle cancellation and increased gonadotrophin consumption are the main encountered problems in ovulation induction regimens of these patients. Therefore, in addition to low success and decreased conception rates, the cost of treatment also increases.
Gonadotrophin-releasing hormone (GnRH) antagonists, due to their reported advantages over GnRH agonists, have more recently been recommended in ovarian stimulation cycles of poor-responders (Fasouliotis, Shapiro and Mitchell-Leef, 2003, D’Amato). Aromatase inhibitors (AI), other recent ovulation induction agents, suppress serum oestradiol concentrations, which results in a subsequent marked increase in serum FSH and LH concentrations. Letrozole, an AI, was reported to be an effective agent both in ovulation induction and in ovarian stimulation without any negative effects on the endometrium (Mitwally and Casper, 2001, Mitwally and Casper, 2002, Mitwally and Casper, 2003, Fisher, Mitwally). Furthermore, treatment with AI together with recombinant FSH (rFSH) in IVF cycles of poor-responders was found to be effective in reducing gonadotrophin consumption and consequently the cost of IVF compared with rFSH-only regimens in GnRH analogue down-regulated cycles (Goswami et al., 2004). In consequence, this study aimed to investigate the efficacy of AI in poor-responders undergoing ovarian stimulation with an GnRH antagonist regimen.
Section snippets
Subjects
A total of 70 infertile women who were planned to undergo their second intracytoplasmic sperm injection (ICSI) – embryo transfer cycle and with a history of poor ovarian response in their first ICSI – embryo transfer cycle were enrolled in the study. Written informed consent was taken from all subjects before initiation of the treatment cycle. All of these enrolled patients had their first ICSI – embryo transfer cycle or the ovarian stimulation scheme at least 6 months prior to the current
Results
Details of infertility aetiologies in each group are given in Table 2. The mean age of participants and the mean basal hormone concentrations were not different among the groups. The mean number of follicles >14 mm or >17 mm on the day of HCG administration, mean number of retrieved oocytes and mean number of mature oocytes were similar in both groups (Table 3). In total, 145 and 107 MII oocytes were retrieved in groups A and B, respectively. However, the mean concentration of serum oestradiol on
Discussion
Aromatase inhibitors have been introduced as an alternative ovulation induction agent either alone (Mitwally and Casper, 2001) or as an adjunctive ovulation induction agent along with gonadotrophins in ovarian stimulation (Mitwally and Casper, 2003). It was reported that transient inhibition of aromatase activity in early follicular phase (on days 5–9) with letrozole results in ovarian stimulation similar to clomiphene citrate with no apparent adverse effect on endometrium (Fisher et al., 2002
References (23)
- et al.
Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial
Fertility and Sterility
(2006) - et al.
Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients
Fertility and Sterility
(2005) - et al.
A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women
Fertility and Sterility
(2002) - et al.
Use of letrozole versus clomiphene citrate combined with gonadotropins in intrauterine insemination cycles: a pilot study
Fertility and Sterility
(2006) - et al.
Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders
Fertility and Sterility
(2002) - et al.
Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate
Fertility and Sterility
(2001) - et al.
Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation
American Journal of Obstetrics and Gynecology
(2005) - et al.
Optimal stimulation protocols for in-vitro fertilization
Fertility and Sterility
(2006) - et al.
Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
Fertility and Sterility
(2008) - et al.
Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate
Fertility and Sterility
(2006)
Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study
Reproductive BioMedicine Online
Cited by (62)
Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis
2022, Reproductive BioMedicine OnlineEffects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: A meta-analysis
2021, Journal of Gynecology Obstetrics and Human ReproductionDouble mild stimulation and egg collection in the same cycle for management of poor ovarian responders
2019, Journal of Gynecology Obstetrics and Human ReproductionIn vitro fertilization treatments with the use of clomiphene citrate or letrozole
2017, Fertility and SterilityA randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response
2016, European Journal of Obstetrics and Gynecology and Reproductive BiologyThe effect of letrozole as an adjunct in GnRH-antagonist protocol on IVF/ICSI outcome in women with endometriosis: a randomized clinical trial
2023, Middle East Fertility Society Journal
- ☆
Dr Batuhan Özmen completed his residency programme in obstetrics and gynaecology at University of Ankara in 2003, obtaining his certification in reproductive medicine and artificial reproductive techniques in 2005. In 2006, he worked in the Department of Obstetrics and Gynecology of the University of Schleswig-Holstein in Lübeck under the supervision of Professor Safaa Al-Hasani on laboratory applications in reproductive medicine. He is interested in cryopreservation and vitrification of human gametes, reproductive surgery and human sperm DNA damage. He is now working in the Department of Reproductive Endocrinology at the University of Ankara, Turkey.Dr Batuhan Özmen